Prominent publications by T Andrew Lister

KOL Index score: 14989

PURPOSE: To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) and to compare its efficacy to the patients' last qualifying chemotherapy (LQC) regimens.

PATIENTS AND METHODS: Sixty patients who had been treated with at least two protocol-specified qualifying chemotherapy regimens and ...

Also Ranks for: 131 Tositumomab |  refractory low |  patients chemotherapy |  hodgkin lymphoma |  corixa corp
KOL Index score: 14699

PURPOSE: To assess long-term site-specific risks of second malignancy after Hodgkin's disease in relation to age at treatment and other factors.

PATIENTS AND METHODS: A cohort of 5,519 British patients with Hodgkin's disease treated during 1963 through 1993 was assembled and followed-up for second malignancy and mortality. Follow-up was 97% complete.

RESULTS: Three hundred twenty-two second malignancies occurred. Relative risks of gastrointestinal, lung, breast, and bone and soft tissue ...

Also Ranks for: Chemotherapy Radiotherapy |  hodgkins disease |  solid cancers |  cancer risk |  modality treatment
KOL Index score: 14563

PURPOSE: The immune microenvironment is key to the pathophysiology of classical Hodgkin lymphoma (CHL). Twenty percent of patients experience failure of their initial treatment, and others receive excessively toxic treatment. Prognostic scores and biomarkers have yet to influence outcomes significantly. Previous biomarker studies have been limited by the extent of tissue analyzed, statistical inconsistencies, and failure to validate findings. We aimed to overcome these limitations by ...

Also Ranks for: Classical Hodgkin Lymphoma |  cd20 antigens |  myelomonocytic biomarkers |  cd68 foxp3 |  tumor microenvironment
KOL Index score: 14563

The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials ...

Also Ranks for: Lugano Classification |  response assessment |  hodgkin lymphoma |  fluorodeoxyglucose f18 |  evaluation staging
KOL Index score: 14217

PURPOSE: A prospective, multicenter, open-label, phase II clinical trial to assess oral fludarabine phosphate treatment in terms of safety, efficacy, and quality of life. Reference to a historical group of patients treated with the intravenous (IV) formulation allowed the two formulations to be compared.

PATIENTS AND METHODS: Patients with previously untreated B-cell chronic lymphocytic leukemia received 10-mg tablets of fludarabine phosphate to a dose of 40 mg/m(2)/d for 5 days, ...

Also Ranks for: Chronic Lymphocytic Leukemia |  oral fludarabine |  quality life |  efficacy safety |  untreated patients
KOL Index score: 13258

PURPOSE: The European Association of Hematopathologists and the Society for Hematopathology have developed a new World Health Organization (WHO) classification of hematologic malignancies, including lymphoid, myeloid, histiocytic, and mast cell neoplasms.

DESIGN: Ten committees of pathologists developed lists and definitions of disease entities. A clinical advisory committee (CAC) of international hematologists and oncologists was formed to ensure that the classification would be useful ...

Also Ranks for: Health Organization |  airlie house |  neoplastic diseases |  clinical advisory committee |  lymphoid neoplasms
KOL Index score: 13079

PURPOSE: To evaluate the incidence of and risk factors for therapy-related myelodysplasia (tMDS) and secondary acute myelogenous leukemia (sAML), after high-dose therapy (HDT) with autologous bone marrow or peripheral-blood progenitor-cell support, in patients with non-Hodgkin's lymphoma (NHL).

PATIENTS AND METHODS: Between January 1985 and November 1996, 230 patients underwent HDT comprising cyclophosphamide therapy and total-body irradiation, with autologous hematopoietic ...

Also Ranks for: Tmds Saml |  autologous hematopoietic |  acute lymphoma |  cell support |  lymphoid malignancies
KOL Index score: 12993

Type-C RNA tumor viruses have been implicated in the etiology of naturally occurring leukemias and lymphomas of animals. Human T-cell leukemia/lymphoma virus (HTLV) is the first human virus of this class consistently identified in association with a specific type of human leukemia/lymphoma. The isolation of HTLV was made possible by the ability to grow mature T-cells in tissue culture usually with T-cell growth factor (TCGF). We now report a cluster of adult T-cell leukemia/lymphoma ...

Also Ranks for: Viral Antigens |  caribbean region |  adult t‐cell leukemia |  lymphoma virus htlv |  human type‐c retrovirus
KOL Index score: 12315

PURPOSE: Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are incurable with standard therapy. A multicenter phase II study was conducted to assess the toxicity and the overall response rates (RR) and complete response (CR) rates to rituximab (chimeric anti-CD20 monoclonal antibody).

PATIENTS AND METHODS: Between January 1997 and January 1998, 131 patients with newly diagnosed MCL (MCL1; n = 34) and ...

Also Ranks for: Cell Lymphoma |  patients mcl |  cd20 monoclonal |  intravenous leukemia |  duration response
KOL Index score: 12158

Gene expression profiles were determined from presentation peripheral blood and bone marrow samples of 28 patients with acute myeloid leukemia (AML). Hierarchical clustering sorted the profiles into separate groups, each representing one of the major cytogenetic classes in AML [i.e., t(8;21), t(15;17), inv(16), 11q23, and normal karyotype]. Statistical group comparison identified genes whose expression was strongly correlated with these chromosomal classes. Moreover, the normal karyotype ...

Also Ranks for: Myeloid Leukemia |  normal karyotype |  gene expression |  acute leukocytes |  fusion rna
KOL Index score: 12120

Bortezomib is a proteasome inhibitor with proven efficacy in multiple myeloma and non-Hodgkin's lymphoma. This study reports the effects of bortezomib in B-cell lymphoma cell lines with differing sensitivity to bortezomib to investigate factors that influence sensitivity. Bortezomib induced a time- and concentration-dependent reduction in cell viability in five lymphoma cell lines, with EC(50) values ranging from 6 nmol/L (DHL-7 cells) to 25 nmol/L (DHL-4 cells) after 72 h. Bortezomib ...

Also Ranks for: Mitotic Catastrophe |  cell lines |  proteasome inhibitor |  bortezomib treatment |  difference sensitivity
KOL Index score: 12102

Aldehyde dehydrogenase (ALDH) is a cytosolic enzyme that is responsible for the oxidation of intracellular aldehydes. Elevated levels of ALDH have been demonstrated in murine and human progenitor cells compared with other hematopoietic cells, and this is thought to be important in chemoresistance. A method for the assessment of ALDH activity in viable cells recently has been developed and made commercially available in a kit format. In this study, we confirmed the use of the ALDH ...

Also Ranks for: Cord Blood |  acute myeloid |  dehydrogenase activity |  aldh cells |  situ hybridization
KOL Index score: 12099

Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterized by platelet abnormalities and a predisposition to myelodysplasia (MDS) and/or acute myeloid leukemia (AML). The disorder, caused by inherited mutations in RUNX1, is uncommon with only 14 pedigrees reported. We screened 10 families with a history of more than one first degree relative with MDS/AML for inherited mutations in RUNX1. Germ- line RUNX1 mutations were ...

Also Ranks for: Runx1 Mutation |  mds aml |  myeloid malignancy |  familial platelet |  hematopoietic stem
KOL Index score: 12078

PURPOSE: To evaluate the long-term results of high-dose therapy (HDT) in follicular lymphoma, with specific emphasis on the prognostic significance of polymerase chain reaction (PCR)-detectable Bcl-2/IgH rearrangements.

PATIENTS AND METHODS: Between June 1985 and October 1995, 99 patients with follicular lymphoma received HDT as consolidation of second or subsequent remission. Bone marrow was treated in vitro with anti-B-cell antibodies and complement.

RESULTS: Sixty-five patients ...

Also Ranks for: Follicular Lymphoma |  bone marrow |  dose therapy |  99 patients |  bcl2 igh

Key People For Follicular Lymphoma

Top KOLs in the world
Randy * ********
cell lymphoma diffuse large gene expression
T ****** ******
follicular lymphoma bone marrow acute leukaemia
Hervé *****
consultancy honoraria board directors advisory committees
Elaine * *****
cell lymphoma lymphoid neoplasms situ hybridization
Richard * ******
southwest oncology cell lymphoma consultancy funding
Bertrand * ********
cell lymphoma monoclonal antibodies elderly patients

T Andrew Lister:Expert Impact

Concepts for whichT Andrew Listerhas direct influence:Follicular lymphoma,  Bone marrow,  Myeloablative therapy,  Acute leukaemia,  131 tositumomab,  Acute myeloid leukemia,  Acute myelogenous leukaemia,  Complete remission.

T Andrew Lister:KOL impact

Concepts related to the work of other authors for whichfor which T Andrew Lister has influence:Follicular lymphoma,  Acute myeloid leukemia,  Bone marrow,  Diffuse large,  Stem cell,  Monoclonal antibodies,  Gene expression.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

St Bartholomew's Hospital London, London, United Kingdom. | Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. | Barts Cancer Institute, Queen Mary University of London, London, UK. | St Bartholomew's Ho